.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Farmers Insurance
Citi
Boehringer Ingelheim
Chubb
UBS
Moodys
Johnson and Johnson
Deloitte
US Department of Justice

Generated: December 14, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,889,190

« Back to Dashboard

Which drugs does patent 8,889,190 protect, and when does it expire?


Patent 8,889,190 protects QUDEXY XR and is included in one NDA. There has been one Paragraph IV challenge on Qudexy XR.

This patent has seven patent family members in five countries.

Summary for Patent: 8,889,190

Title:Extended-release topiramate capsules
Abstract: An extended-release topiramate capsule that includes a capsule shell containing a single population of coated particles; wherein each coated particle includes a core and a coating thereon; wherein each particle core includes a homogeneous mixture comprising topiramate throughout its core; and wherein the coating includes one or more release controlling agent(s).
Inventor(s): Betterman; Sarah Michelle (Champlin, MN), Tantry; Jaidev Srinivas (Maple Grove, MN), Patrick; Laura Marie (Eden Prairie, MN)
Assignee: Upsher-Smith Laboratories, Inc. (Maple Grove, MN)
Application Number:14/157,646
Patent Claim Types:
see list of patent claims
Composition; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Upsher-smith LabsQUDEXY XRtopiramateCAPSULE, EXTENDED RELEASE;ORAL205122-001Mar 11, 2014RXYesNo► Subscribe► Subscribe► SubscribeY
Upsher-smith LabsQUDEXY XRtopiramateCAPSULE, EXTENDED RELEASE;ORAL205122-002Mar 11, 2014RXYesNo► Subscribe► Subscribe► SubscribeY
Upsher-smith LabsQUDEXY XRtopiramateCAPSULE, EXTENDED RELEASE;ORAL205122-003Mar 11, 2014RXYesNo► Subscribe► Subscribe► SubscribeY
Upsher-smith LabsQUDEXY XRtopiramateCAPSULE, EXTENDED RELEASE;ORAL205122-004Mar 11, 2014RXYesNo► Subscribe► Subscribe► SubscribeY
Upsher-smith LabsQUDEXY XRtopiramateCAPSULE, EXTENDED RELEASE;ORAL205122-005Mar 11, 2014RXYesYes► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,889,190

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,652,527Extended-release topiramate capsules► Subscribe
9,555,005Extended-release topiramate capsules► Subscribe
9,101,545Extended-release topiramate capsules► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,889,190

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
South Korea20160124930► Subscribe
South Korea20150132838► Subscribe
South Korea101674509► Subscribe
Israel241053► Subscribe
Canada2905011► Subscribe
European Patent Office2968177► Subscribe
World Intellectual Property Organization (WIPO)2014143380► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Cipla
Boehringer Ingelheim
Moodys
Teva
Accenture
Farmers Insurance
Medtronic
AstraZeneca
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot